[ A23-98] Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48
Last updated 17.11.2023
Project no.:
A23-98
Commission:
Commission awarded on 11.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
- Patients < 65 years who are eligible for high-dose therapy: indication of major added benefit
- Patients ≥ 65 years who are eligible for high-dose therapy: indication of considerable added benefit
- Patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who are not eligible for high-dose therapy: added benefit not proven
- Patients with primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B who are not eligible for high-dose therapy: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-98
| Project no. | Title | Status |
|---|---|---|
| A23-48 | Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.